Golcadomide: all 23 studies that test it
Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaNot yet recruitingNCT07917832Phase 2
- A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionRecruitingNCT07763418Phase 1
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasNot yet recruitingNCT07608731Phase 1
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07578077Phase 1/2
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07269639Phase 1/2
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingNCT07018752Phase 1/2
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingNCT06911502Phase 3
- A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)RecruitingNCT06835530Phase 2
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingNCT06834373Phase 2
- Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of RelapseRecruitingNCT06271057Phase 2
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaRecruitingNCT06209619Phase 1
- Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular LymphomaRecruitingNCT06108232Phase 2
- Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell TherapyWithdrawnNCT06767956Phase 1/2
- Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedNCT06535399Phase 1
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruitingNCT06425302Phase 2
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaActive, not recruitingNCT06356129Phase 3
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingNCT06035497Phase 1/2
- Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.Active, not recruitingNCT05788081Phase 2
- A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male ParticipantsCompletedNCT05567510Phase 1
- A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy ParticipantsCompletedNCT05350800Phase 1
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingNCT04884035Phase 1
- A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT04434196Phase 1
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingNCT03930953Phase 1/2